Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo
- Paul R Gorry1, 2, 3Email author,
- Dale A McPhee2, 4, 6,
- Erin Verity1, 4, 6,
- Wayne B Dyer7, 8,
- Steven L Wesselingh1, 2, 3,
- Jennifer Learmont7,
- John S Sullivan7, 8,
- Michael Roche1,
- John J Zaunders9,
- Dana Gabuzda11, 12,
- Suzanne M Crowe1, 3,
- John Mills3, 4, 5,
- Sharon R Lewin3, 13,
- Bruce J Brew10,
- Anthony L Cunningham14 and
- Melissa J Churchill1
© Gorry et al; licensee BioMed Central Ltd. 2007
Received: 06 July 2007
Accepted: 23 September 2007
Published: 23 September 2007
In efforts to develop an effective vaccine, sterilizing immunity to primate lentiviruses has only been achieved by the use of live attenuated viruses carrying major deletions in nef and other accessory genes. Although live attenuated HIV vaccines are unlikely to be developed due to a myriad of safety concerns, opportunities exist to better understand the correlates of immune protection against HIV infection by studying rare cohorts of long-term survivors infected with attenuated, nef-deleted HIV strains such as the Sydney blood bank cohort (SBBC). Here, we review studies of viral evolution, pathogenicity, and immune responses to HIV infection in SBBC members. The studies show that potent, broadly neutralizing anti-HIV antibodies and robust CD8+ T-cell responses to HIV infection were not necessary for long-term control of HIV infection in a subset of SBBC members, and were not sufficient to prevent HIV sequence evolution, augmentation of pathogenicity and eventual progression of HIV infection in another subset. However, a persistent T-helper proliferative response to HIV p24 antigen was associated with long-term control of infection. Together, these results underscore the importance of the host in the eventual outcome of infection. Thus, whilst generating an effective antibody and CD8+ T-cell response are an essential component of vaccines aimed at preventing primary HIV infection, T-helper responses may be important in the generation of an effective therapeutic vaccine aimed at blunting chronic HIV infection.
Despite considerable effort, all attempts to develop an effective human immunodeficiency virus (HIV) vaccine based on subunit or prime-boost strategies have failed to elicit sterilizing immunity and protect against infection with wild type virus (reviewed in [1–3]). Current World Health Organization estimates indicate 42 million people are infected with HIV and approximately 20 million have died from AIDS. Approximately 5 million new infections occur annually. The overwhelming majority of these individuals live in developing countries with little or no access to potentially lifesaving antiretroviral therapies. Moreover, HIV is predicted to become the leading burden of disease in middle and low income countries by 2015 . Thus, the need for an effective preventative and/or therapeutic HIV vaccine has never been more urgent.
Since the discovery of HIV nearly 25 years ago, there have been significant advances in our knowledge of HIV immunology (reviewed in [5–7]). As early as 1990 subunit vaccines based on the HIV envelope protein were developed, based on the observation that vaccinated chimpanzees were protected against homologous HIV challenge . However, it is unlikely that such vaccines will ever be able to illicit immune responses sufficient for protection against heterologous HIV strains and, in fact, these approaches have failed repeatedly in animal models. In addition, HIV envelope protein-based vaccines were not efficacious in 2 phase III vaccine trials in humans [9–12]. More sophisticated vaccine approaches have targeted cellular immunity by the development of DNA prime-boost strategies, and have achieved strong stimulation of antibody and cytotoxic T-lymphocyte (CTL) responses in monkeys. However, despite robust immunological responses, these strategies have ultimately failed to protect against challenge infection. A better understanding of the correlates of immune protection against HIV infection would greatly assist efforts to develop an effective HIV vaccine [13, 14].
Epidemiology and Clinical History of the Sydney blood bank cohort
Clinical history of SBBC members
Date of Birth
Clinical History and other informationa
N/A; infected with HIV-1 sexually, 12/1980
ABC, AZT, NVP (1/1999-9/2004) ABC, NVP, 3TC (9/2004-present)
Diagnosed with moderate HIVD, 12/1998; SP.
D4T, NVP, IND (11/1999-death)
Prednisone since 1995 for asthma; died 3/30/2001 from bronchial amyloidosis; death not related to HIV; SP.
IDDM; HCV; surgery for colon cancer in 1995; died 8/28/2001 from myocardial infarct; death not related to HIV; SP.
Diagnosed with age-onset diabetes in 2004, managed by diet; chronic alcoholism; LTNP.
Hypertension; hypercholesterolemia; LTNP.
CCR5Δ32 heterozygote; HLA-B57 positive; LTNP.
Severe coronary atherosclerosis; died 11/1995 from bacterial pneumonia; death not related to HIV; LTNP.
Prednisone since 1982 for SLE; intermittent cyclophosphamide, azathioprine, hydrocortisone; died from combined PCP and pneumococcal pneumonia 4/1987; uncertain if death was HIV related; HIV Progression status uncertain
Died from metastatic gastric cancer 10/1994. Death not related to HIV; HIV Progression status uncertain.
HIV isolates and viral phenotypes
Phenotypes of nef-deleted viruses isolated from SBBC members, and corresponding laboratory data
CD4 cells (cells/μl)
HIV RNA (copies/ml)
Replication in PBMC
CCR5, CXCR4, (CCR2b)
CCR5, CXCR4, (CCR2b)
CCR5, CXCR4, (CCR2b)
CCR5, CXCR4, (CCR2b)
CCR5, (CCR3, Gpr15)
CCR5, (CCR3, Gpr15)
CCR5, (CCR2b, CCR3)
CCR5, (CCR2b, CCR3)
CCR5, (CCR2b, CCR3)
CCR5, (CCR2b, CCR3)
CCR5, (CCR2b, CCR3)
When compared with wild type HIV isolates and isogenic controls with mutations in nef, replication capacity of SBBC isolates in PHA-activated PBMC was found to be consistent over time by viruses isolated from a particular subject, but heterogenous between subjects and fell into 3 distinct phenotypes [28, 40] (Table 2). Viruses isolated from C18 replicated rapidly to high levels similar to wild type HIV; viruses isolated from D36 and C98 replicated to lower levels; and viruses isolated from C54 and C64 were barely able to replicate to detectable levels. In contrast, all isolates replicated to equivalent levels in the Cf2-luc reporter cell line [41, 43, 44] expressing CD4, CCR5 and CXCR4. Thus, SBBC isolates except those from C18 appear to have attenuated replication capacity in PHA-activated PBMC. Inhibiting the in vivo replication of HIV in D36 by HAART demonstrated a prolonged in vivo virion half life, with a first-phase slope of decline of HIV RNA 0.18/day  which is slower than that seen in all previously studied individuals infected with wild-type HIV after commencement of ART [46–49]. Thus, the replication kinetics of D36 virus appears to be attenuated both in vitro and in vivo.
Analysis of coreceptor usage in transfected Cf2-Luc cells  showed that all isolates used CCR5 (R5) as the primary coreceptor for HIV entry, except viruses isolated from D36 prior to commencement of HAART which were dual tropic and used CCR5 and CXCR4 (R5X4) [28, 40] (Table 2). These results showed that nef-deleted HIV was capable of undergoing a coreceptor switch from R5 to R5X4 in vivo. An isolate obtained from D36 after commencement of HAART was CCR5-restricted and had features of an early archived HIV variant, but was genetically similar to HIV present in a CSF sample obtained from D36 during HIV-associated dementia (HIVD) . Thus, for D36, HIV present in CSF during HIVD was likely to be an early variant that underwent compartmentalized evolution in the CNS. Moreover, we showed for the first time that nef-deleted HIV is inherently capable of undergoing compartmentalized evolution in the CNS and causing neurologic disease in humans . Stepwise quasispecies diversity was observed in SBBC SP, whereas C49 displayed stable quasispecies diversity most similar to early variants in the SBBC (B. Herring et al., manuscript submitted). Extended analysis of alternative coreceptor usage showed that D36 and C54 isolates could use CCR2b, C18 and C54 isolates could use CCR3, and C18 isolates could use Gpr15 for HIV entry, albeit at low levels  (Table 2). Whether expanded usage of alternative HIV coreceptors by SBBC isolates contributes to HIV pathogenesis in these individuals is uncertain, but the unique signature of coreceptor usage for viruses isolated from different SBBC members suggests independent evolution for each virus after infection of each cohort member. This interpretation is consistent with results of Env heteroduplex tracking assays, Env heteroduplex mobility assays and Env V1V2 length polymorphism assays which also demonstrated independent evolution of HIV Env in each subject (, and B. Herring et al., manuscript submitted).
Changes in HIV pathogenicity
To better understand changes in pathogenicity which may have contributed to HIV progression in D36, Jekle et al  used an ex vivo human lymphoid cell culture system to analyze the ability of 2 HIV viruses isolated from D36 to deplete CD4+ T-cells; one isolated in 1995 prior to the onset of AIDS (D36II) and another isolated in 1999 after the onset of disease progression (D36XI) (Table 2). Although both D36 isolates were less potent in depleting CD4+ T-cells than reference X4 and R5X4 isolates with intact nef genes, the 1999 isolate induced greater levels of CD4+ T-cell cytotoxicity than the 1995 isolate. Differences in CD4+ T-cell cytotoxicity between the 2 isolates were evident in CD4+/CCR5- cells, but not evident in CD4+/CCR5+ cells suggesting an increased ability to use CXCR4 by the 1999 isolate. Further studies with the CXCR4 inhibitor AMD3100 showed that, although both isolates were functionally R5X4 [28, 40] (Table 2), the 1999 isolate had preferential use of CXCR4 whereas the 1995 isolate had preferential use of CCR5 for HIV entry. These studies showed evolution of R5X4 strains in D36 to a variant with higher cytopathic potential that was associated with increased use of CXCR4 in vitro and HIV progression in vivo.
Consistent with results of the study by Jekle et al , we showed alterations in HIV cytopathicity by sequential D36 isolates in cultures of monocyte-derived macrophages (MDM). Compared with the highly macrophage tropic R5 ADA and R5X4 89.6 isolates, all D36 viruses replicated in MDM to low levels and had delayed replication kinetics . There was no evidence of increased HIV replication in MDM by virus isolated from D36 after HIV progression. However, in support of the results obtained by Jekle et al , the 1999 isolate caused extensive cytopathicity in MDM similar to that present in cultures infected with ADA or 89.6, characterized by the presence of many syncytia . In contrast, earlier D36 isolates caused only few or occasional syncytia in MDM despite all D36 viruses replicating in MDM to similar levels. Thus, increased cytopathicity in MDM by the 1999 D36 isolate is most likely due to intrinsic pathogenic features of the Env that increase fusogenicity, similar to that which has been observed by particular neurotropic R5 and R5X4 viruses [53–55]. The increased Env fusogenicity may have contributed to greater cytopathicity by the 1999 D36 isolate and HIV progression in D36. Further studies to elucidate the molecular determinants of D36 Env that are associated with increased fusogenicity are in progress.
The effect of long-term infection with nef-deleted virus on CD4+ T cells was studied in detail for six SBBC members . Careful comparison with age- and transfusion-matched controls revealed the surprising result that SBBC members had an increased number of circulating CD45RO+ memory CD4+ T cells. This was unexpected, since these CD4+ T cells are widely believed to represent the main target of cytopathic HIV infection [57–60] (reviewed in ), and loss of these cells ultimately leads to acquired immunodeficiency. Therefore, this result is consistent with the hypothesis that nef-deleted HIV has reduced pathogenicity in vivo.
Nevertheless, in the SBBC subjects studied with detectable plasma viral load, C54 and C98, there was concomitant elevation of CD8+ T cell activation, whereas the SBBC subjects with undetectable plasma viral load, C49, C64 and C135 had normal levels of CD8+ T cell activation . Therefore, within the SBBC, the situation was similar to the strong correlation seen between plasma viral load and CD8+ T-cell activation in subjects infected with wild type HIV . Furthermore, as described above, subjects D36, C98 and C54 exhibited a clear CD4+ T cell decline, albeit at a relatively slow rate [28–30]. This interesting finding argues that pathogenicity within the SBBC was more closely correlated with levels of viral replication (as assessed by plasma viral load) and CD8+ T-cell activation than with viral pathogenicity dictated by the presence or absence of nef. This finding likely represents the ability of host factors to modulate the pathogenicity of nef-deleted HIV-1 [63, 64]. CD8+ T cell activation may reflect lymphocyte turnover during HIV infection, which has been proposed to lead to disruption of normal homeostasis and eventual consumption of both memory and naïve CD4+ T cells [65, 66]. However, we did not find evidence of dramatically increased CD4+ T cell turnover in these subjects, as determined by expression of Ki-67 as a marker of cell proliferation .
Evolution of nef/LTR sequence
Reversion to pathogenicity by nef-deleted SIV has been associated with restoration of a truncated Nef protein , acquisition of further deletions in the nef/LTR overlap region , and/or duplications of NF-κB binding sites in the LTR . In contrast to the SIV studies, the in vivo evolution of nef-deleted HIV in SBBC members was unidirectional toward a smaller nef/LTR sequence and the majority of the additional sequence loss was within the nef-alone region . Furthermore, none of the clones were capable of encoding Nef. Together, these results suggest improved viral replication by further deleting remnants of the nef gene. In addition, the presence of duplicated NF-κB binding sites in the LTR was not associated with clinical status of the SBBC subjects. Therefore, it is likely that viral factors that modulate the in vivo pathogenicity of nef-deleted HIV will be distinct from those in nef-deleted SIV. Interestingly, the unidirectional evolution toward the minimal nef/LTR sequence observed in SBBC members was strikingly similar to the pattern of evolution in a slow progressor infected with a nef/LTR-deleted variant of HIV circulating recombinant form 01_AE . The convergent pattern of nef/LTR evolution among viruses harboured by SBBC members is therefore unlikely to be due to a unique property of the infecting strain, but rather a positive selection that is common across clades.
Changes in transcriptional activity
Viruses harbored by SBBC members contain unique alterations of NF-κB and Sp-1 binding sites in the LTR that may affect transcriptional activity and thus, replication capacity [28, 29, 32]. Therefore, we examined the nucleotide sequence and transcriptional activity of nef/LTR clones obtained sequentially from D36 blood samples and from D36 CSF obtained during HIVD, to determine whether changes in LTR activity may contribute to neuropathogenesis of nef-deleted HIV-1 infection . We found that the transcriptional activity of CSF-derived nef/LTR clones was up to 4.5-fold higher than blood-derived clones isolated before and during HIVD when tested under basal, PMA- and Tat-activated conditions. The presence of duplicated NF-κB and Sp-1 binding sites or a truncated nef sequence in blood-derived nef/LTRs was not sufficient to mediate large increases in transcriptional activity. However, CSF-derived nef/LTRs had duplicated NF-κB and Sp-1 binding sites coupled with a truncated nef sequence, which formed a regulatory unit that significantly enhanced LTR transcription .
Previous studies showed that LTR variants with augmented transcriptional activity enhance replication of HIV . Therefore, to determine whether D36 nef/LTRs affect replication capacity of HIV in vitro, we produced and characterized full-length chimeric molecular clones of HIV NL4-3 carrying the nef/LTR nucleotide sequence of blood-derived D36 nef/LTRs or the CSF-derived D36 nef/LTR . We examined the capacity of chimeric NL4-3 viruses carrying D36 nef/LTRs to replicate in PBMC compared with wild type NL4-3 and the NL4-3ΔNef deletion mutant . Compared to wild type NL4-3, chimeric HIV containing the nef/LTR sequence of blood derived D36 viruses had attenuated replication kinetics, similar to NL4-3ΔNef. In contrast, chimeric HIV containing the nef/LTR of D36 CSF had enhanced replication capacity compared to wild type NL4-3. Thus, the nef/LTR derived from CSF of D36, which had augmented basal, PMA- and Tat-activated transcriptional activity compared to wild type and blood-derived D36 nef/LTRs, augmented replication of HIV in PBMC. Together, our results suggest unique features of the CSF-derived nef/LTR restore efficient replication capacity of nef-deleted HIV in PBMC by enhancing transcription. The results further suggest that nef and LTR mutations that augment transcription may contribute to neuropathogenesis of nef-deleted HIV.
Attenuation in other HIV genes
In addition to nef and LTR, mutations or polymorphisms in other HIV genes including gag, rev, tat, vif, vpr, vpu and env have been detected in SP or LTNP [71–78]. A previous study of HIV rev alleles isolated from a subject with long-term nonprogressive HIV infection showed a persistent Leu to Ile change at position 78 in the Rev activation domain which attenuated Rev function and HIV replication capacity , providing evidence that defective rev alleles may contribute to long-term survival of HIV infection in some patients. A subsequent study of naturally occurring rev alleles with rare sequence variations in the activation domain showed variable reductions in Rev activity , although it was unclear from this study whether the observed reductions in Rev activity would be sufficient to attenuate HIV replication capacity. Of note, CTL escape mutations in the second coding exon of Tat have been shown to attenuate virus in vivo, suggesting that in vivo sequence changes in other regulatory HIV-1 genes may potentially affect HIV-1 pathogenesis . Since differences in HIV pathogenicity in SBBC members could not be fully explained by alterations in the nef/LTR region  or Env phenotype [40, 50], we characterized dominant HIV-1 rev alleles that persisted in SBBC LTNP (C18, C64) and SP (C98, D36) . We found that the ability of Rev derived from D36 and C64 to bind the Rev responsive element (RRE) in RNA binding assays was reduced by approximately 90% compared to Rev derived from NL4-3, C18 or C98. D36 Rev also had a 50–60% reduction in ability to express Rev-dependent reporter constructs in mammalian cells. In contrast, C64 Rev had only marginally decreased Rev function despite attenuated RRE binding. In D36 and C64, we found that attenuated RRE binding was associated with rare amino acid changes at 3 highly conserved residues; Gln to Pro at position 74 immediately N-terminal to the Rev activation domain, and Val to Leu and Ser to Pro at positions 104 and 106 at the Rev C-terminus, respectively. In D36, reduced Rev function and altered replication capacity was mapped to an unusual 13 amino acid extension at the Rev C-terminus. However, database analysis of rev sequence demonstrated that the presence of one or more of these rare amino acid changes was not able to discriminate between subjects with progressive or non-progressive HIV-1 infection. Moreover, none of these amino acid changes occurred in a previously identified LTNP with defective rev alleles . Thus, our studies suggest the contribution of any or all of these mutations to decreased RRE binding and/or attenuated Rev function by SBBC Revs, and possibly to slow or absent HIV progression, is likely to be context dependent.
It is presently unclear whether attenuated D36 Rev function in vitro equates to attenuated Rev function in vivo, and indeed whether attenuated Rev function contributed to slow progression of HIV infection in this subject. Extrapolation of these in vitro findings to an in vivo role for attenuated D36 rev alleles is difficult, since this subject and other SBBC members are infected with virus containing gross nef/LTR deletions which have been shown to cause significant viral attenuation in this cohort [28, 29, 32]. Nonetheless, our findings raise the possibility that attenuated Rev function may contribute, at least in part, to viral attenuation and slow HIV progression in D36.
Anti-HIV Ig responses
To better understand the humoral immune response to nef-deleted HIV infection, we measured the total IgG responses in longitudinal plasma samples of SBBC members by Western blotting, and compared these with total IgG responses in a control group of LTNP with intact nef genes . We found a good correlation between total IgG responses in SBBC members and a detectable plasma VL, with plasma from C18, C54, D36 and C98 all being strongly reactive. Subjects C49 and C64, who consistently maintained undetectable HIV RNA copy numbers [29, 30], had significantly reduced total IgG responses. Furthermore, subject C135, who has also had consistently undetectable HIV RNA levels has not fully seroconverted after more than 20 years of infection [40, 42]. These studies highlight the importance of adequate antigenic stimulation by nef-deleted HIV to drive antibody production. In contrast, we found that total IgG responses in the control group were uniformly potent, reflecting the fact that all these individuals had detectable VLs. Among SBBC members, the strongest antibody responses were observed in individuals with low but detectable VL set points, less than approximately 10,000 RNA copies/ml. This is consistent with a recent observation of an undetectable VL and weak, delayed antibody responses in an unrelated individual with nef-deleted HIV .
Recent studies have highlighted the change in HIV antibody responses with respect to antibody isotype switching after initial infection, in particular IgG3 reactivity to p24 [82, 83]. Preliminary WB testing of p24 IgG3 responses in the SBBC LTNP indicated there was reactivity for those individuals with the most potent total IgG responses (C18 and C54) (E. Verity, D. McPhee, K. Wilson, and D. Zotos, unpublished data). This hints at delayed isotype switching and hence delayed maturation of immune responses for at least some members of the SBBC.
Neutralization studies of nef-deleted HIV
In additional studies, we determined whether plasma from SBBC members had differences in ability to neutralize nef-deleted HIV strains. We did this by comparing the ability of longitudinally collected plasma from SBBC members or from control LTNP cohort members to neutralize the infectivity of HIV isolated from D36 and C18 . We found that, for SBBC plasmas, neutralization of D36 or C18 viruses strongly correlated with VL, replication capacity of the isolated virus, and the strength of anti-HIV IgG responses. Plasma from SBBC members with undetectable VL was unable to neutralize the infectivity of these viruses. In contrast, plasmas from the control LTNP cohort were able to neutralize the infectivity of SBBC viruses with titres generally higher than that seen for SBBC members, but there was no correlation between neutralization and HIV RNA copy number or IgG responses in the control LTNP group.
Broad neutralizing antibody responses
A number of studies have suggested an increased frequency of LTNP and long term survivors (LTS) possess strong, cross-reactive neutralising antibody responses [84–86]. However, very few studies have investigated antibody responses in LTNP/LTS infected with nef-deleted HIV, despite a number of studies showing strong neutralising antibody responses in macaques infected with nef-deleted SIV [87–92]. However, studies by Greenough et al.,  showed measurable neutralising antibody responses concurrent with a detectable VL for a single individual infected with nef-defective HIV. We therefore determined the breadth of neutralizing antibodies against HIV for SBBC members.
We found that plasma from C18, and to a lesser extent D36, C54 and C98 were able to potently neutralize the infectivity of a number of laboratory adapted and primary HIV strains, but little or no neutralizing activity was evident in plasma from C49, C64 and C135 . Further analysis of cross reacting neutralizing antibodies in SBBC plasma demonstrated that plasma derived from C18 was able to potently neutralize the infectivity of HIV-1ROK39 (clade A), HIV-1SE364 (clade C), HIV-1BCB93 (clade D), and HIV-192TH024 (CRF01_AE), while plasma derived from C98 was able to only weakly neutralize the infectivity of HIV-1ROK39 and HIV-1SE364 .
Together, our studies on antibody responses in SBBC members demonstrated that infection with nef-deleted HIV can, in some individuals, induce antibody responses capable of potently neutralizing a broad range of isolates. It is possible that the breadth of antibody responses observed in SBBC members may be associated with unrestricted immunoglobulin class switching, which is inhibited by Nef . This would be counterbalanced by the very low viral replication in vivo (VL) and a detectable IgG3 p24 response for C18 and C54. Hence, the broad antibody response may also reflect an early response to infection. The strongest antibody responses in SBBC members were observed in individuals with a detectable VL, supporting the model of a VL threshold which must be reached to provide adequate antigenic stimulation to drive antibody production . However, this higher level of virus replication places these individuals at greatest risk of disease progression. Signs of disease progression were observed for 2 SBBC members (D36, C98) [28–30], demonstrating that the potent neutralizing antibody responses observed did not protect from disease progression. These results question the effectiveness of a broad neutralizing antibody response in individuals with established infection. However, this does not preclude an important role for neutralizing antibodies in preventing initial infection.
Analysis of cellular immune mechanisms suppressing nef-deleted virus in SBBC nonprogressors may provide insights relevant for HIV vaccine design. Several studies have demonstrated that the presence of a sustained Gag-specific CD8+ T-cell response is associated with protection against disease progression in cohorts of LTNP infected with nef-intact HIV [95–97]. In support, our studies have also shown that the distinguishing feature of LTNP harbouring nef-intact HIV is the predominance of Gag-specific CD8+ T-cell responses, which decline when these individuals start to progress (W.B. Dyer et al., manuscript in preparation). However, novel qualitative and quantitative differences in immune correlates of viral control may exist in LTNP infected with nef-deleted HIV. Longitudinal studies of T-cell responses in SBBC members have demonstrated a dominance of Pol-specific CD8+ T-cell responses rather than those against Gag  and W.B. Dyer et al., manuscript in preparation). This suggests that infection with nef-deleted HIV may give rise to a qualitatively different response, although a subset of SBBC members also had strong CD8+ T-cell responses to Gag . Nonetheless, CD8+ T-cell responses to Gag or Pol did not discriminate SBBC LTNP from SP.
The development of an effective HIV vaccine has been hampered by the lack of defined correlates of immune protection against HIV infection. Although nef-deleted strains of HIV are not suitable as live attenuated HIV vaccines due to safety concerns, the only lentiviral vaccines to date that have generated sterilizing immunity in animals are those based on live, attenuated viruses. To this end, studies of SBBC members naturally "vaccinated" with nef-deleted HIV may provide unique insights into protective immune responses to HIV infection, which may assist the development of an effective HIV vaccine. As a consortium, we have been studying nef-deleted HIV infection in the SBBC for a number of years, linking changes in pathogenicity in vivo with viral evolution and immune responses to infection. The major aim of this review was to summarize our recently published and unpublished studies on the SBBC. Together, the studies show that potent, broadly neutralizing anti-HIV antibodies and robust CD8+ T-cell responses to HIV infection were not necessary for long-term control of HIV infection in a subset of SBBC members, and were not sufficient to prevent HIV sequence evolution, augmentation of pathogenicity and eventual progression of HIV infection in another subset. However, a strong T-helper proliferative response to HIV p24 antigen was associated with long-term control of infection. Variation in the outcome of HIV infection in this cohort appears to be strongly host-dependent, consistent with other studies with wild-type HIV. Dependence upon the host's unique immune environment also appears to be important in contributing to control of infection. This further complicates development of a successful vaccine. We hope that results gleaned thus far from studies of this unique cohort of individuals will provide HIV vaccine researchers with novel insights into immune mechanisms that may serve to prevent or control HIV infection.
We thank Marcel Hijnen for assistance with artwork. This study was supported in part by a multicenter program grant to SLW, SMC, SRL, BJB and ALC from the Australian National Health and Medical Research Council (NHMRC) (358399), grants to PRG from the Australian NHMRC (251520, 433915) and NIH/NIAID (AI054207), a grant to DAM from the American Foundation for AIDS Research (amfAR) (106669) and by a grant to MJC from the Australian National Center for HIV Virology Research. PRG is the recipient of an NHMRC R. Douglas Wright Biomedical Career Development Award.
- Duerr A, Wasserheit JN, Corey L: HIV vaccines: new frontiers in vaccine development. Clin Infect Dis. 2006, 43 (4): 500-511. 10.1086/505979.View ArticlePubMedGoogle Scholar
- Letvin NL: Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol. 2006, 6 (12): 930-939. 10.1038/nri1959.View ArticlePubMedGoogle Scholar
- McMichael AJ: HIV vaccines. Annu Rev Immunol. 2006, 24: 227-255. 10.1146/annurev.immunol.24.021605.090605.View ArticlePubMedGoogle Scholar
- Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3 (11): e442-10.1371/journal.pmed.0030442.PubMed CentralView ArticlePubMedGoogle Scholar
- Chinen J, Shearer WT: Molecular virology and immunology of HIV infection. J Allergy Clin Immunol. 2002, 110 (2): 189-198. 10.1067/mai.2002.126226.View ArticlePubMedGoogle Scholar
- Letvin NL, Walker BD: Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003, 9 (7): 861-866. 10.1038/nm0703-861.View ArticlePubMedGoogle Scholar
- Spearman P: Current progress in the development of HIV vaccines. Curr Pharm Des. 2006, 12 (9): 1147-1167. 10.2174/138161206776055859.View ArticlePubMedGoogle Scholar
- McMichael AJ, Hanke T: HIV vaccines 1983-2003. Nat Med. 2003, 9 (7): 874-880. 10.1038/nm0703-874.View ArticlePubMedGoogle Scholar
- Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005, 191 (5): 654-665. 10.1086/428404.View ArticlePubMedGoogle Scholar
- Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M: HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis. 2005, 192 (6): 974-983. 10.1086/432734.View ArticlePubMedGoogle Scholar
- Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW: Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis. 2005, 191 (5): 666-677. 10.1086/428405.View ArticlePubMedGoogle Scholar
- Graham BS, Mascola JR: Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. J Infect Dis. 2005, 191 (5): 647-649. 10.1086/428406.View ArticlePubMedGoogle Scholar
- Pantaleo G, Koup RA: Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med. 2004, 10 (8): 806-810. 10.1038/nm0804-806.View ArticlePubMedGoogle Scholar
- Whitney JB, Ruprecht RM: Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis. 2004, 17 (1): 17-26. 10.1097/00001432-200402000-00004.View ArticlePubMedGoogle Scholar
- Singh M: No vaccine against HIV yet--are we not perfectly equipped?. Virol J. 2006, 3: 60-10.1186/1743-422X-3-60.PubMed CentralView ArticlePubMedGoogle Scholar
- Klase Z, Donio MJ, Blauvelt A, Marx PA, Jeang KT, Smith SM: A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames. Retrovirology. 2006, 3: 1-10.1186/1742-4690-3-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Mosca JD, Chang YN, Williams G: Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents. Retrovirology. 2007, 4: 32-10.1186/1742-4690-4-32.PubMed CentralView ArticlePubMedGoogle Scholar
- Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC: Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol. 1999, 73 (10): 8356-8363.PubMed CentralPubMedGoogle Scholar
- Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol. 1996, 70 (6): 3724-3733.PubMed CentralPubMedGoogle Scholar
- Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992, 258 (5090): 1938-1941. 10.1126/science.1470917.View ArticlePubMedGoogle Scholar
- Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet. 1995, 345 (8961): 1342-1344. 10.1016/S0140-6736(95)92540-6.View ArticlePubMedGoogle Scholar
- Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000, 6 (2): 200-206. 10.1038/72309.View ArticlePubMedGoogle Scholar
- Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM: Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis. 2004, 189 (12): 2167-2173. 10.1086/420833.View ArticlePubMedGoogle Scholar
- Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL: Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999, 73 (5): 4009-4018.PubMed CentralPubMedGoogle Scholar
- Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000, 6 (2): 207-210. 10.1038/72318.View ArticlePubMedGoogle Scholar
- Sawai ET, Hamza MS, Ye M, Shaw KE, Luciw PA: Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J Virol. 2000, 74 (4): 2038-2045. 10.1128/JVI.74.4.2038-2045.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, Anderson DC, O'Neil S, Ruprecht RM: Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. Aids. 2003, 17 (2): 157-166. 10.1097/00002030-200301240-00004.View ArticlePubMedGoogle Scholar
- Churchill M, Sterjovski J, Gray L, Cowley D, Chatfield C, Learmont J, Sullivan JS, Crowe SM, Mills J, Brew BJ, Wesselingh SL, McPhee DA, Gorry PR: Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J Infect Dis. 2004, 190 (12): 2181-2186. 10.1086/425585.View ArticlePubMedGoogle Scholar
- Churchill MJ, Rhodes DI, Learmont JC, Sullivan JS, Wesselingh SL, Cooke IR, Deacon NJ, Gorry PR: Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J Virol. 2006, 80 (2): 1047-1052. 10.1128/JVI.80.2.1047-1052.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS: Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med. 1999, 340 (22): 1715-1722. 10.1056/NEJM199906033402203.View ArticlePubMedGoogle Scholar
- Birch MR, Learmont JC, Dyer WB, Deacon NJ, Zaunders JJ, Saksena N, Cunningham AL, Mills J, Sullivan JS: An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J Clin Virol. 2001, 22 (3): 263-270. 10.1016/S1386-6532(01)00198-6.View ArticlePubMedGoogle Scholar
- Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maertz S, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995, 270 (5238): 988-991. 10.1126/science.270.5238.988.View ArticlePubMedGoogle Scholar
- Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC: Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med. 1995, 332 (4): 228-232. 10.1056/NEJM199501263320405.View ArticlePubMedGoogle Scholar
- Kondo M, Shima T, Nishizawa M, Sudo K, Iwamuro S, Okabe T, Takebe Y, Imai M: Identification of attenuated variants of HIV-1 circulating recombinant form 01_AE that are associated with slow disease progression due to gross genetic alterations in the nef/long terminal repeat sequences. Journal of Infectious Diseases. 2005, 192: 56-61. 10.1086/430739.View ArticlePubMedGoogle Scholar
- Mariani R, Kirchhoff F, Greenough TC, Sullivan JL, Desrosiers RC, Skowronski J: High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol. 1996, 70 (11): 7752-7764.PubMed CentralPubMedGoogle Scholar
- Rhodes DI, Ashton L, Solomon A, Carr A, Cooper D, Kaldor J, Deacon N: Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. J Virol. 2000, 74 (22): 10581-10588. 10.1128/JVI.74.22.10581-10588.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Salvi R, Garbuglia AR, Di Caro A, Pulciani S, Montella F, Benedetto A: Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol. 1998, 72 (5): 3646-3657.PubMed CentralPubMedGoogle Scholar
- Learmont J, Tindall B, Evans L, Cunningham A, Cunningham P, Wells J, Penny R, Kaldor J, Cooper DA: Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet. 1992, 340 (8824): 863-867. 10.1016/0140-6736(92)93281-Q.View ArticlePubMedGoogle Scholar
- Gorry PR, Churchill M, Learmont J, Cherry C, Dyer WB, Wesselingh SL, Sullivan JS: Replication-dependent pathogenicity of attenuated, nef-deleted HIV-1 in vivo. Journal of Acquired Immune Deficiency Syndromes. 2007, In press.-Google Scholar
- Verity E, Zotos D, Wilson K, Chatfield C, Lawson VA, Dwyer D, Cunningham A, Learmont J, Dyer W, Sullivan J, Churchill M, Wesselingh SL, Gabuzda D, Gorry PR, McPhee D: Viral phenotypes and antibody responses in long term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef/long terminal repeat region. J Virol. 2007, 81: 9268-9278. 10.1128/JVI.00650-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, Bell JE, Bannert N, Crawford K, Wang H, Schols D, De Clercq E, Kunstman K, Wolinsky SM, Gabuzda D: Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity. J Virol. 2001, 75 (21): 10073-10089. 10.1128/JVI.75.21.10073-10089.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Rhodes D, Solomon A, Bolton W, Wood J, Sullivan J, Learmont J, Deacon N: Identification of a new recipient in the Sydney Blood Bank Cohort: a long-term HIV type 1-infected seroindeterminate individual. AIDS Res Hum Retroviruses. 1999, 15 (16): 1433-1439. 10.1089/088922299309946.View ArticlePubMedGoogle Scholar
- Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, Lee J, Sodroski J: Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol. 2000, 74 (9): 4433-4440. 10.1128/JVI.74.9.4433-4440.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Gray L, Sterjovski J, Churchill M, Ellery P, Nasr N, Lewin SR, Crowe SM, Wesselingh S, Cunningham AL, Gorry PR: Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology. 2005, 337: 384-398. 10.1016/j.virol.2005.04.034.View ArticlePubMedGoogle Scholar
- Crowe SM, Ho DD, Marriott D, Brew B, Gorry PR, Sullivan JS, Learmont J, Mills J: In vivo replication kinetics of a nef-deleted strain of HIV-1. Aids. 2005, 19 (8): 842-843. 10.1097/01.aids.0000168984.05209.f1.View ArticlePubMedGoogle Scholar
- Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997, 387 (6629): 188-191. 10.1038/387188a0.View ArticlePubMedGoogle Scholar
- Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996, 271 (5255): 1582-1586. 10.1126/science.271.5255.1582.View ArticlePubMedGoogle Scholar
- Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995, 373 (6510): 117-122. 10.1038/373117a0.View ArticlePubMedGoogle Scholar
- Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MM: Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis. 1999, 179 (4): 799-807. 10.1086/314670.View ArticlePubMedGoogle Scholar
- Gray L, Churchill MJ, Sterjovski J, Witlox K, Learmont J, Sullivan JS, Wesselingh SL, Gabuzda D, Cunningham AL, McPhee DA, Gorry PR: Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long term survivors infected from a single source. Virology Journal. 2007, 4: 75-10.1186/1743-422X-4-75.PubMed CentralView ArticlePubMedGoogle Scholar
- Jekle A, Schramm B, Jayakumar P, Trautner V, Schols D, De Clercq E, Mills J, Crowe SM, Goldsmith MA: Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol. 2002, 76 (14): 6966-6973. 10.1128/JVI.76.14.6966-6973.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Gorry PR, McPhee DA, Wesselingh SL, Churchill MJ: Macrophage tropism and cytopathicity of HIV-1 variants isolated sequentially from a long-term survivor infected with nef-deleted virus. The Open Microbiology Journal. 2007, 1: 1-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang H, Bell JE, Kunstman K, Moore JP, Wolinsky SM, Gabuzda D: Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. Journal of Virology. 2002, 76 (12): 6277-6292. 10.1128/JVI.76.12.6277-6292.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Ohagen A, Ghosh S, He J, Huang K, Chen Y, Yuan M, Osathanondh R, Gartner S, Shi B, Shaw G, Gabuzda D: Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope. Journal of Virology. 1999, 73 (2): 897-906.PubMed CentralPubMedGoogle Scholar
- Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, Simmonds P, Clapham PR: Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J Virol. 2004, 78 (13): 6915-6926. 10.1128/JVI.78.13.6915-6926.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Zaunders JJ, Geczy AF, Dyer WB, McIntyre LB, Cooley MA, Ashton LJ, Raynes-Greenow CH, Learmont J, Cooper DA, Sullivan JS: Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes. AIDS Res Hum Retroviruses. 1999, 15 (17): 1519-1527. 10.1089/088922299309801.View ArticlePubMedGoogle Scholar
- Chun TW, Chadwick K, Margolick J, Siliciano RF: Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI. J Virol. 1997, 71 (6): 4436-4444.PubMed CentralPubMedGoogle Scholar
- Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C: Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science. 1999, 284 (5415): 816-819. 10.1126/science.284.5415.816.View ArticlePubMedGoogle Scholar
- Lapenta C, Parlato S, Spada M, Santini SM, Rizza P, Logozzi M, Proietti E, Belardelli F, Fais S: Human lymphoblastoid CD4(+) T cells become permissive to macrophage-tropic strains of human immunodeficiency virus type 1 after passage into severe combined immunodeficient mice through in vivo upregulation of CCR5: in vivo dynamics of CD4(+) T-cell differentiation in pathogenesis of AIDS. J Virol. 1998, 72 (12): 10323-10327.PubMed CentralPubMedGoogle Scholar
- Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS: Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A. 1990, 87 (16): 6058-6062. 10.1073/pnas.87.16.6058.PubMed CentralView ArticlePubMedGoogle Scholar
- Kelleher AD, Zaunders JJ: Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection. Curr HIV/AIDS Rep. 2006, 3 (1): 5-12. 10.1007/s11904-006-0002-5.View ArticlePubMedGoogle Scholar
- Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R, Smith D, Grey P, Vizzard J, Carr A, Cooper DA: Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis. 1999, 180 (2): 320-329. 10.1086/314880.View ArticlePubMedGoogle Scholar
- O'Brien SJ, Moore JP: The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev. 2000, 177: 99-111. 10.1034/j.1600-065X.2000.17710.x.View ArticlePubMedGoogle Scholar
- Roger M: Influence of host genes on HIV-1 disease progression. Faseb J. 1998, 12 (9): 625-632.PubMedGoogle Scholar
- Hazenberg MD, Hamann D, Schuitemaker H, Miedema F: T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol. 2000, 1 (4): 285-289. 10.1038/79724.View ArticlePubMedGoogle Scholar
- McCune JM: The dynamics of CD4+ T-cell depletion in HIV disease. Nature. 2001, 410 (6831): 974-979. 10.1038/35073648.View ArticlePubMedGoogle Scholar
- Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, Mansfield K, Desrosiers RC: Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J Virol. 2003, 77 (12): 6823-6835. 10.1128/JVI.77.12.6823-6835.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Churchill MJ, Figueiredo A, Cowley D, Gray L, Purcell DF, Sullivan JS, McPhee DA, Wesselingh SL, Brew BJ, Gorry PR: Transcriptional activity of blood-and cerebrospinal fluid-derived nef/long-terminal repeat sequences isolated from a slow progressor infected with nef-deleted human immunodeficiency virus type 1 (HIV-1) who developed HIV-associated dementia. J Neurovirol. 2006, 12 (3): 219-228. 10.1080/13550280600827369.View ArticlePubMedGoogle Scholar
- Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, Berkhout B: Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J Virol. 2000, 74 (8): 3740-3751. 10.1128/JVI.74.8.3740-3751.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Gorry P, Purcell D, Howard J, McPhee D: Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication. Journal of Neurovirology. 1998, 4 (4): 377-386.View ArticlePubMedGoogle Scholar
- Shioda T, Oka S, Xin X, Liu H, Harukuni R, Kurotani A, Fukushima M, Hasan MK, Shiino T, Takebe Y, Iwamoto A, Nagai Y: In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. J Virol. 1997, 71 (7): 4871-4881.PubMed CentralPubMedGoogle Scholar
- Wang B, Spira TJ, Owen S, Lal RB, Saksena NK: HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors. Aids. 2000, 14 (3): 213-223. 10.1097/00002030-200002180-00002.View ArticlePubMedGoogle Scholar
- Iversen AK, Shpaer EG, Rodrigo AG, Hirsch MS, Walker BD, Sheppard HW, Merigan TC, Mullins JI: Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol. 1995, 69 (9): 5743-5753.PubMed CentralPubMedGoogle Scholar
- Alexander L, Aquino-DeJesus MJ, Chan M, Andiman WA: Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J Virol. 2002, 76 (20): 10533-10539. 10.1128/JVI.76.20.10533-10539.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Binley JM, Jin X, Huang Y, Zhang L, Cao Y, Ho DD, Moore JP: Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression. J Virol. 1998, 72 (4): 3472-3474.PubMed CentralPubMedGoogle Scholar
- Wang B, Ge YC, Palasanthiran P, Xiang SH, Ziegler J, Dwyer DE, Randle C, Dowton D, Cunningham A, Saksena NK: Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology. 1996, 223 (1): 224-232. 10.1006/viro.1996.0471.View ArticlePubMedGoogle Scholar
- Yamada T, Iwamoto A: Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch Virol. 2000, 145 (5): 1021-1027. 10.1007/s007050050692.View ArticlePubMedGoogle Scholar
- Michael NL, Chang G, d'Arcy LA, Ehrenberg PK, Mariani R, Busch MP, Birx DL, Schwartz DH: Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol. 1995, 69 (7): 4228-4236.PubMed CentralPubMedGoogle Scholar
- Hua J, Caffrey JJ, Cullen BR: Functional consequences of natural sequence variation in the activation domain of HIV-1 Rev. Virology. 1996, 222 (2): 423-429. 10.1006/viro.1996.0439.View ArticlePubMedGoogle Scholar
- Smith SM, Pentlicky S, Klase Z, Singh M, Neuveut C, Lu CY, Reitz MS, Yarchoan R, Marx PA, Jeang KT: An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. J Biol Chem. 2003, 278 (45): 44816-44825. 10.1074/jbc.M307546200.View ArticlePubMedGoogle Scholar
- Churchill M, Chiavaroli L, Wesselingh SL, Gorry PR: Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus. Retrovirology. 2007, 4: 43-10.1186/1742-4690-4-43.PubMed CentralView ArticlePubMedGoogle Scholar
- Adalid-Peralta L, Grangeot-Keros L, Rudent A, Ngo-Giang-Huong N, Krzysiek R, Goujard C, Deveau C, Le Gall M, Meyer L, Emilie D, Rouzioux C: Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. HIV Med. 2006, 7 (8): 514-519. 10.1111/j.1468-1293.2006.00406.x.View ArticlePubMedGoogle Scholar
- Wilson KM, Johnson EI, Croom HA, Richards KM, Doughty L, Cunningham PH, Kemp BE, Branson BM, Dax EM: Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. Aids. 2004, 18 (17): 2253-2259. 10.1097/00002030-200411190-00005.View ArticlePubMedGoogle Scholar
- Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J: Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. Aids. 1998, 12 (13): 1591-1600. 10.1097/00002030-199813000-00005.View ArticlePubMedGoogle Scholar
- Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis. 1997, 176 (4): 924-932.View ArticlePubMedGoogle Scholar
- Zhang YJ, Fracasso C, Fiore JR, Bjorndal A, Angarano G, Gringeri A, Fenyo EM: Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis. 1997, 176 (5): 1180-1187.View ArticlePubMedGoogle Scholar
- Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, Leech S, Smith JD, Rud EW, Dennis MJ, Hall GA: Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology. 1997, 229 (1): 143-154. 10.1006/viro.1996.8419.View ArticlePubMedGoogle Scholar
- Enose Y, Ui M, Miyake A, Suzuki H, Uesaka H, Kuwata T, Kunisawa J, Kiyono H, Takahashi H, Miura T, Hayami M: Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology. 2002, 298 (2): 306-316. 10.1006/viro.2002.1440.View ArticlePubMedGoogle Scholar
- Igarashi T, Ami Y, Yamamoto H, Shibata R, Kuwata T, Mukai R, Shinohara K, Komatsu T, Adachi A, Hayami M: Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. J Gen Virol. 1997, 78 ( Pt 5): 985-989.View ArticleGoogle Scholar
- Kumar A, Mukherjee S, Shen J, Buch S, Li Z, Adany I, Liu Z, Zhuge W, Piatak M, Lifson J, McClure H, Narayan O: Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Virology. 2002, 301 (2): 189-205. 10.1006/viro.2002.1544.View ArticlePubMedGoogle Scholar
- Montefiori DC, Baba TW, Li A, Bilska M, Ruprecht RM: Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. J Immunol. 1996, 157 (12): 5528-5535.PubMedGoogle Scholar
- Stipp HL, Kumar A, Narayan O: Characterization of immune escape viruses from a macaque immunized with live-virus vaccine and challenged with pathogenic SHIVKU-1. AIDS Res Hum Retroviruses. 2000, 16 (15): 1573-1580. 10.1089/088922200750006092.View ArticlePubMedGoogle Scholar
- Greenough TC, Somasundaran M, Brettler DB, Hesselton RM, Alimenti A, Kirchhoff F, Panicali D, Sullivan JL: Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 1994, 10 (4): 395-403.View ArticlePubMedGoogle Scholar
- Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A: Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol. 2006, 7 (3): 302-310. 10.1038/ni1302.View ArticlePubMedGoogle Scholar
- Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F: Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis. 1998, 178 (4): 1008-1018.View ArticlePubMedGoogle Scholar
- Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, Lopez O, Pialoux G, Feuillie V, Mollereau M, Chamaret S, et al: Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses. 1995, 11 (8): 903-907.View ArticlePubMedGoogle Scholar
- Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, Njovu L, Geis S, Hoffmann O, Maboko L, Williamson C, Birx D, Meyerhans A, Cox J, Hoelscher M: CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol. 2007, 81 (5): 2440-2448. 10.1128/JVI.01847-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Dyer WB, Ogg GS, Demoitie MA, Jin X, Geczy AF, Rowland-Jones SL, McMichael AJ, Nixon DF, Sullivan JS: Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J Virol. 1999, 73 (1): 436-443.PubMed CentralPubMedGoogle Scholar
- Dyer WB, Geczy AF, Kent SJ, McIntyre LB, Blasdall SA, Learmont JC, Sullivan JS: Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. Aids. 1997, 11 (13): 1565-1574. 10.1097/00002030-199713000-00004.View ArticlePubMedGoogle Scholar
- Dyer WB, Kuipers H, Coolen MW, Geczy AF, Forrester J, Workman C, Sullivan JS: Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets. AIDS Res Hum Retroviruses. 2002, 18 (14): 999-1010. 10.1089/08892220260235362.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.